Ultragenyx announces approval of Crysvita in Brazil
Ultragenyx announced that Brazil’s National Health Surveillance Agency has approved Crysvita for the treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.